The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
External validation of the Molecular International Prognostic Scoring System (IPSS-M) for myelodysplastic syndromes.
 
Brian Chernak
No Relationships to Disclose
 
Abdullah Ali
Stock and Other Ownership Interests - TFC Therapeutics
Consulting or Advisory Role - TFC Therapeutics; VOR Biopharma
Research Funding - Actinium Pharmaceuticals; GRAIL; Rarecells; Vor Biopharma
Patents, Royalties, Other Intellectual Property - Licensing fee, milestone payments, and royalties from VOR Biopharma.
 
Amna Jan
No Relationships to Disclose
 
Sanjay Mukherjee
No Relationships to Disclose
 
Joseph G. Jurcic
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Novartis; Rigel; Syros Pharmaceuticals
Research Funding - Astellas Pharma (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb/Celgene (Inst); Celularity (Inst); FORMA Therapeutics (Inst); Gilead/Forty Seven (Inst); Ionis Pharmaceuticals (Inst); Sumitomo Dainippon Pharma Oncology (Inst)
 
Azra Raza
Leadership - GRAIL
Stock and Other Ownership Interests - TFC Therapeutics
Honoraria - Epizyme; Taiho Oncology
Consulting or Advisory Role - Genzyme; Janssen; Takeda; TFC Therapeutics
Research Funding - GRAIL; Immuneel Therapeutics; Rarecells; Regeneron
Travel, Accommodations, Expenses - GRAIL; Rarecells